OpenEvidence Is Turning Hospital Data and Pharma Ad Money Into Its Own Drug Pipeline

Two hospitals in 48 hours

OpenEvidence collected two academic medical centers in 48 hours. On 15 September, Penn Medicine put the AI in front of more than 10,000 clinicians across seven hospitals, extending it through the Botswana-UPenn Partnership ¹. A day later, Memorial Sloan Kettering went further: OncoKB, the precision oncology knowledge base built over 14 years, now answers inside OpenEvidence for every clinician on the platform, while OpenEvidence embeds in MSK's Epic charts ². It is the only somatic cancer variant knowledge base with partial FDA recognition, held since October 2021 ³⁴.

The distributor's price moved in the same news cycle: Forbes↗ disclosed a previously unreported $250 million round led by Byers Capital and Andreessen Horowitz at a $15 billion valuation ³, nineteen months after a $1 billion valuation ⁵.

Pharma pays at the prescribing moment

The tool is free to every verified US clinician, and 1.12 million of them used it as of September, posting more than 40 million queries in August ⁶. The cash is advertising, much of it pharmaceutical, placed between a doctor's question and the cited answer ⁷. An analysis by Nelson Advisors↗ estimates specialist impressions at $70 to more than $1,000 per thousand, against $5 to $15 on consumer platforms, on roughly $300 million of run-rate revenue at margins near 90% ⁸. Nadler told NBC News↗ in May that the ad model may not be the one the company keeps ⁷. What no source shows: whether the ads change what doctors prescribe, and what MSK charged for its crown jewels.

The database becomes a drug pipeline

MSK calls the deal "a distribution mechanism" for its expertise ³. Nadler's plans run the other way: OncoKB, paired with the NCCN guidelines OpenEvidence already licenses ⁶, feeds a proprietary therapy pipeline, a first drug in trials before year-end and three to five more next year, starting with rare cancers where community practices can locate trial patients cheaply ³. "We are not going to compete with Lilly or Pfizer to do 10,000 patient nation-scale trials," he said ³.

MSK traded reach; OpenEvidence keeps the pipeline

Hospitals supply the knowledge, pharma advertisers supply the cash, OpenEvidence keeps the pipeline. One check on the moat: OncoKB stays free for academic use and is licensed commercially without exclusivity, so MSK parted with reach, not ownership ⁴. What compounds is the middle position: more than half of US hematologist-oncologists already route their hardest questions through one company ², and their patients' treatment decisions pass through the same ad-funded layer. Nothing in either announcement↗ flows back to MSK beyond distribution. Next readings: the first trial, promised before year-end, and further cancer-center deals Nadler said were weeks away ⁶.